PBH Stock Analysis: Buy, Sell, or Hold?
PBH - Prestige Consumer Healthcare Inc.
$57.68
-1.59 (-2.68%)
▼
5d:
-5.64%
30d:
-16.41%
90d:
-7.34%
HOLD
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When PBH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PBH shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: PBH shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$81.45
Based on 5.0% avg growth
INTRINSIC VALUE TODAY
$50.57
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBH is currently trading at $57.68, which is considered oversold relative to its 30-day fair value range of $60.07 to $68.13. The stock's valuation (Forward PE: 12.0) is in line with its historical norms (13.3). Remarkably, the market is currently pricing in an annual earnings decline of 3.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PBH is in a uptrend. The price is currently testing key support at $58.32. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PBH has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $78.50 (+36.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PBH is in a uptrend. The price is currently testing key support at $58.32. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PBH has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $78.50 (+36.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$60.07 -
$68.13
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 36.1% below Wall St target ($78.50)
- CAUTION: 5-day price weakness (-5.6%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$60.07 -
$68.13
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$58.32
Resistance Level
$64.48
Current Trend
Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.99
Wall Street Target
$78.50
(+36.1%)
Revenue Growth (YoY)
-2.4%
Earnings Growth (YoY)
-20.5%
Profit Margin
16.9%
Valuation Discount vs History
-3.5% cheaper
PE vs Historical
12.0 vs 13.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.5%
(market-implied from PE analysis)
1-Year Target
$55.66
(-4%)
2-Year Target
$53.71
(-7%)
3-Year Target
$51.83
(-10%)
3-Yr Target (if PE normalizes)
(PE: 12→13)
$57.49
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 5.9%)
$127.85
(+122%)
Base:
(SPY PE: 12.0, Growth: 5.9%)
$68.60
(+19%)
Bear:
(PE: 10.2, Growth: 5.9%)
$58.31
(+1%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 16.09 | Current EPS (TTM): $3.79
Bull Case
$84.86
(+35%)
Analyst growth 26.5%, PE expands to 17.7
Base Case
$77.14
(+23%)
Market implied 26.5%, PE stable at 16.1
Bear Case
$41.47
(-34%)
Severe decline -20.0%, PE contracts to 13.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.0 to 13.3
Stabilization Target:
$63.97
(+10.9%)
PE Expansion Potential:
+10.9%
Share & Embed Analysis
Last updated: April 02, 2026 9:02 AM ET
Data refreshes hourly during market hours. Next update: 10:02 AM
Data refreshes hourly during market hours. Next update: 10:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Jeffrey Zerillo
SELL
1000 shares
2026-02-11
Jeffrey Zerillo
SELL
281 shares
2025-12-01
Jeffrey Zerillo
SELL
719 shares
2025-11-28
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 65 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 65 BUY |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$38 | 64 BUY |
